Novo Nordisk, the Danish maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, was cut to a sell rating by Deutsche Bank on Thursday, a rare bearish call on a company that has lost roughly 70% of its market value from its peak.
The downgrade stands out because Wall Street analysts had largely resisted advising investors to abandon the stock, even as its share price slid steadily over the past year. Deutsche Bank’s move breaks with that reluctance, signaling deeper concern about the company’s ability to defend its dominance in the obesity-treatment market.
Novo Nordisk once ranked among Europe’s most valuable listed companies, powered by surging demand for its GLP-1 medications. That momentum has since reversed. Intensifying competition, most notably from U.S. rival Eli Lilly and its weight-loss drug Zepbound, has eroded the Danish firm’s early lead and pressured its growth outlook.
Recent clinical setbacks have added to the strain. The company’s shares dropped sharply earlier this year after its heart drug Ziltivekimab stumbled in a late-stage trial, denying Novo Nordisk a potential new avenue for growth beyond its core franchises.
Behind the numbers, the challenge is commercial as much as scientific. Cheaper compounded versions of its drugs, pricing pressure in the United States, and slowing prescription growth have combined to shake confidence in the company’s earnings trajectory. The steep decline from peak levels reflects investors repricing what had been priced as near-unlimited expansion.
For a company whose treatments reshaped how obesity and diabetes are managed for millions of patients, the reversal has been swift. The sell rating suggests analysts now expect further downside rather than a near-term recovery, a notable shift in sentiment for a former market darling.
Novo Nordisk faces the task of stabilizing its pipeline and defending market share against Eli Lilly, while convincing investors that its next generation of obesity treatments can restore the growth that once justified its lofty valuation. The coming quarters, and its results updates, will test whether the downgrade proves prescient or premature.